Nifty Pharma News and Updates

Name: Latest research reports of Zydus Lifesciences Ltd. authored by KRChoksey and published by - Trendlyne research reports.
Item: Zydus Lifesciences Ltd.
Rating: 5
Author: KRChoksey

Keep track of all breaking news on Nifty Pharma from all sources in a single place.

Load latest

Alkem Laboratories Ltd.

07 Feb 2025

4981.55

1.92%

Alkem Laboratories Results Earnings Call for Q3FY25

Conference Call with Alkem Laboratories Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.

Alkem Laboratories Ltd.

07 Feb 2025

4981.55

1.92%

to see Rapid results content

Aurobindo Pharma Ltd.

07 Feb 2025

1220.95

5.45%

to see Rapid results content

Cipla Ltd.

07 Feb 2025

1513.45

4.21%

Cipla stock shows strength on charts, adopt Bull Spread: Nandish Shah

Business Standard

Cipla share price: The short-term trend turned positive as Cipla stock price closed above its 5 and 11 day EMA

Cipla Ltd.'s price crossed above 100Day SMA today

Zydus Lifesciences Ltd.

07 Feb 2025

933.75

4.78%

New product launches is set to drive growth in US

Buy: Zydus Lifesciences Ltd.

KRChoksey

Zydus Lifesciences’ revenue was largely in-line with our estimates. EBITDA missed our estimates due to lower-than-expected gross profit and higher-than-expected other expenses. However, Adj. PAT was in-line with our estimates as EBITDA miss was offset by lower-than-expected tax expenses.

Zydus Lifesciences Ltd.'s price crossed above 50Day SMA today

Aurobindo Pharma Ltd.

06 Feb 2025

1220.95

5.45%

Aurobindo Pharma Q3FY25 results: PAT falls 10% to Rs 845.56 crore

Business Standard

Company board approves purchase of 80 per cent share in step-down subsidiary Tergene Biotech

Aurobindo Pharma Ltd. has an average target of 1501.00 from 10 brokers.

Aurobindo Pharma Q3 Results: Profit Falls 9.7%, Misses Estimates

NDTV Profit | 06 Feb 2025

Dr. Reddy's Laboratories Ltd.

06 Feb 2025

1212.70

5.45%

Dr Reddy's Unit Ties Up With Shanghai Henlius Biotech

NDTV Profit

As part of the tie-up, Henlius will be responsible for development, manufacturing and commercial supply, and may receive up to a total of $131.6 million.

Dr. Reddy's Laboratories Ltd.'s price crossed above 30Day SMA today

Abbott India Ltd.

06 Feb 2025

30199.85

2.23%

Abbott India gains 10% in 2 days after posting healthy Q3 show; Details

Business Standard

The company's Q3 profit increased 16 per cent year-on-year (Y-o-Y) to Rs 360.78 crore as compared to Rs 310.98 crore

Abbott India Ltd. is trading above its 200 day SMA of 28627.3

J B Chemicals & Pharmaceuticals Ltd.

06 Feb 2025

1578.25

0.74%

JB Chemicals Q3 Review Domestic Biz, CMO To Drive Growth; Nirmal Bang Hikes Target Price, Maintains 'Buy'

NDTV Profit

JB Chemicals remains Nirmal Bang's top pharma pick, supported by strong domestic and CDMO growth, high return ratios, and a lean balance sheet.

J B Chemicals & Pharmaceuticals Ltd. is trading below all available SMAs

JB Chemicals Q3 PAT rises 21 pc to 162 cr

livemint | 06 Feb 2025

Abbott India Ltd.

06 Feb 2025

30199.85

2.23%

Stellar quarter; growth pace accelerating

Buy: Abbott India Ltd.

Target

ICICI Securities Limited

Abbott India’s (Abbott) impressive revenue growth of 12.3% YoY in Q3FY25 was ahead of our expectation. As per IQVIA, this may be driven by key brands of Novo Nordisk like Rybelsus and Ryzodeg and owned brands like Duphalac, Udiliv and Thyronorm.

Abbott India Ltd. is trading above its 200 day SMA of 28627.3

No results found

Is Nifty Pharma worth buying?

303 Votes:

Buy 79.21%

Sell 11.55%

Hold 9.24%

Nifty Pharma PB	5.1
Nifty Pharma PE	33.1
Nifty Pharma DIV	0.7
Nifty Pharma EPS	632.6

Nifty Pharma PB

Nifty Pharma PE

Nifty Pharma DIV

Nifty Pharma EPS

Nifty Pharma News and Updates

Keep track of all breaking news on Nifty Pharma from all sources in a single place.